Compare Cytokinetics Inc (CYTK) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Ryanair Holdings plc — how do they compare? Cytokinetics Inc trades at $81.99 (market cap $11.12B), while Ryanair Holdings plc trades at $64.3 (market cap $31.19B). The key difference: Ryanair Holdings plc is far larger — about 2.8× Cytokinetics Inc's market cap, and Ryanair Holdings plc pays a 1.54% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | RYAAY | |
|---|---|---|
Market Cap | $11.12B | $31.19B |
Sector | Technology | Industrials |
52-Week High | $87.26 | $73.82 |
52-Week Low | $33.23 | $53.24 |
Enterprise Value | $11.59B | $28.85B |
Dividend Yield | — | 1.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
RYAAY trades at $63.91, down 1.14% today, with a bullish technical signal from moving averages and neutral oscillators. The company shows strong profitability with a 13.98% net income margin and 25.37% ROE, supported by consistent earnings beats in recent quarters. Recent news includes a window incident investigation and CEO contract extension, while passenger traffic grew 7% year-over-year in June 2026 (Zacks Investment Research, 2026-07-02).
The outlook remains positive with analyst consensus at 62.5% buy ratings, though risks include rising fuel costs and regulatory scrutiny. Valuation appears reasonable with a P/E of 13.74 and EV/EBITDA of 6.57, suggesting potential upside if travel demand sustains. Near-term focus is on Q2 2026 earnings against expectations of $1.37 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
